You have not created a stock watchlist. Create one now to track $SRRK!
Scholar Rock Holding Corp
Health Care
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious dis… more
Conversation Volume
Last 60 days
There is not enough conversation volume about this stock
Key Opinion Leaders
Strongest 30-day focus on $SRRK by total mentions
Loading data...
Real-time Chart
Price Chart for $SRRK
Conviction History
Bullish vs Bearish Conviction over the last 30 days.
This color denotes Market Hours (US/Eastern)
There is not enough conversation volume about this stock
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is also developing a pipeline of novel product candidates with potential to transform the lives of patients suffering from a range of serious diseases, including neuromuscular disorders, cancer, fibrosis, and iron-restricted anemia. The company has a collaboration agreement with Gilead Sciences, Inc. to discover and develop specific inhibitors of transforming growth factor beta activation for the treatment of fibrotic diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.
We've detected you're running a Microsoft browser so features may not work as expected. We strongly recommend you run Captain runs on the latest versions of Google Chrome, Firefox, or Safari.